Single-time-point dosimetry in [ 177 Lu]Lutetiumvipivotide tetraxetan therapy: systematic evaluation of day-1 imaging as a surrogate of multi-time-point dosimetry across organs, systems and treatment cycles

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

J. Donoso 1, 2; Y. Cras 3; K. Trabelsi 1; H. Noamen 1; A. L. Daverio 1; M. Borsali 1; L. Agrigoroaie 1; D. Deandreis 1; C. Garcia 1

Sep 29, 2026